These findings are analogous to results from large randomized trials in heart failure populations that included a large proportion of patients with CKD and low eGFR and demonstrated consistent effects of SGLT2 inhibitors on cardiovascular death or hospitalization for heart failure irrespective of sex, diabetes, eGFR, or NT-proBNP at baseline.13 Here, SLC5A2 is linked to chronic kidney disease.